<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.23421.007</object-id><label>Table 1.</label><caption><p>Proportions of clinical characteristics in Dataset1 and Dataset2,&#160;<xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p>Histology and TNM stage were based on pathology were available.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23421.007">http://dx.doi.org/10.7554/eLife.23421.007</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"><break/></th><th valign="top">Dataset1</th><th valign="top">Dataset2</th></tr></thead><tbody><tr><td valign="top">Gender</td><td valign="top"><break/></td><td valign="top"><break/></td></tr><tr><td valign="top">Male</td><td valign="top">100 (45%)</td><td valign="top">59 (68%)</td></tr><tr><td valign="top">Female</td><td valign="top">124 (55%)</td><td valign="top">28 (32%)</td></tr><tr><td valign="top">Histology</td><td valign="top"><break/></td><td valign="top"><break/></td></tr><tr><td valign="top">Adenocarcinoma</td><td valign="top">129 (58%)</td><td valign="top">42 (48%)</td></tr><tr><td valign="top">Squamous</td><td valign="top">61 (27%)</td><td valign="top">33 (38%)</td></tr><tr><td valign="top">Other</td><td valign="top">34 (15%)</td><td valign="top">12 (14%)</td></tr><tr><td valign="top">Stage</td><td valign="top"><break/></td><td valign="top"><break/></td></tr><tr><td valign="top">I</td><td valign="top">123 (55%)</td><td valign="top">39 (45%)</td></tr><tr><td valign="top">II</td><td valign="top">35 (15%)</td><td valign="top">26 (30%)</td></tr><tr><td valign="top">III</td><td valign="top">46 (21%)</td><td valign="top">12 (14%)</td></tr><tr><td valign="top">Other</td><td valign="top">20 (9%)</td><td valign="top">10 (11%)</td></tr><tr><td valign="top">Smoking Status</td><td valign="top"><break/></td><td valign="top"><break/></td></tr><tr><td valign="top">Current</td><td valign="top">66 (29%)</td><td valign="top">NA</td></tr><tr><td valign="top">Former</td><td valign="top">141 (63%)</td><td valign="top">NA</td></tr><tr><td valign="top">None</td><td valign="top">17 (8%)</td><td valign="top">NA</td></tr><tr><td valign="top">Tumor site</td><td valign="top"><break/></td><td valign="top"><break/></td></tr><tr><td valign="top">Primary</td><td valign="top">224 (100%)</td><td valign="top">87 (100%)</td></tr><tr><td valign="top">Endpoints</td><td valign="top"><break/></td><td valign="top"><break/></td></tr><tr><td valign="top">Overall survivals</td><td valign="top">134 (60%)</td><td valign="top">41 (47%)</td></tr><tr><td valign="top">Overall deaths</td><td valign="top">90 (40%)</td><td valign="top">46 (53%)</td></tr><tr><td valign="top">Follow up <break/>(median months)</td><td>32</td><td>31</td></tr></tbody></table></table-wrap>